ES2109377T3 - Proceso para la preparacion de una dispersion solida. - Google Patents

Proceso para la preparacion de una dispersion solida.

Info

Publication number
ES2109377T3
ES2109377T3 ES92925333T ES92925333T ES2109377T3 ES 2109377 T3 ES2109377 T3 ES 2109377T3 ES 92925333 T ES92925333 T ES 92925333T ES 92925333 T ES92925333 T ES 92925333T ES 2109377 T3 ES2109377 T3 ES 2109377T3
Authority
ES
Spain
Prior art keywords
drug
preparation
solid dispersion
polymer
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92925333T
Other languages
English (en)
Inventor
Isaac Ghebre-Sellassie
Robert Reisch Jr
Riten Parikh
Mahdi B Fawzi
Russell U Nesbitt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2109377T3 publication Critical patent/ES2109377T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Colloid Chemistry (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Glanulating (AREA)
  • Ceramic Products (AREA)
  • Pigments, Carbon Blacks, Or Wood Stains (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)

Abstract

UNA NUEVA DISPERSION SOLIDA FARMACEUTICA QUE MEJORE LA BIODISPONIBILIDAD DE FARMACOS QUE SE DISUELVEN MAL EN AGUA SE PRODUCE A BASE DE COMBINAR EL FARMACO CON UN SOPORTE POLIMERICO TAL COMO POLIVINILPIRROLIDONA. SI SE UTILIZA UN COMPUESTO DE TRANSICION TAL COMO POLIETILENGLICOL, QUE SOLUBILIZA PARCIALMENTE EL FARMACO Y/O PLASTIFICA EL POLIMERO, NO ES NECESARIA LA UTILIZACION DE SOLVENTES ORGANICOS NI DE TEMPERATURAS DE DERRETIMIENTO (FUSION) AL COMBINAR EL FARMACO CON EL SOPORTE.
ES92925333T 1991-12-18 1992-11-18 Proceso para la preparacion de una dispersion solida. Expired - Lifetime ES2109377T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80965691A 1991-12-18 1991-12-18

Publications (1)

Publication Number Publication Date
ES2109377T3 true ES2109377T3 (es) 1998-01-16

Family

ID=25201894

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92925333T Expired - Lifetime ES2109377T3 (es) 1991-12-18 1992-11-18 Proceso para la preparacion de una dispersion solida.

Country Status (17)

Country Link
US (3) US6677362B1 (es)
EP (1) EP0617612B1 (es)
JP (1) JP3722293B2 (es)
AT (1) ATE157864T1 (es)
AU (1) AU671811B2 (es)
CA (1) CA2124821C (es)
DE (1) DE69222182T2 (es)
DK (1) DK0617612T3 (es)
ES (1) ES2109377T3 (es)
GR (1) GR3025501T3 (es)
IL (1) IL104179A (es)
MX (1) MX9207390A (es)
NZ (1) NZ245483A (es)
PT (1) PT101132B (es)
SG (1) SG43179A1 (es)
WO (1) WO1993011749A1 (es)
ZA (1) ZA929789B (es)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0182801B1 (ko) * 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
ES2109377T3 (es) 1991-12-18 1998-01-16 Warner Lambert Co Proceso para la preparacion de una dispersion solida.
US5688510A (en) * 1993-11-18 1997-11-18 Nippon Shinyaku Co. Ltd. Process for producing stable medicinal composition, and pharmaceutical preparation
SE9502244D0 (sv) * 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
DE09003265T1 (de) 1996-06-26 2010-04-29 Board of Regents, The University of Texas System, Austin Extrudierbare pharmazeutische Schmelzklebstoffformulierung
EP0954288B1 (en) * 1996-06-28 2004-08-11 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
HN1998000115A (es) * 1997-08-21 1999-06-02 Warner Lambert Co Formas de dosificación farmacéuticas sólidas
CA2214895C (en) * 1997-09-19 1999-04-20 Bernard Charles Sherman Improved pharmaceutical composition comprising fenofibrate
US6107341A (en) * 1997-12-19 2000-08-22 Bissell Homecare, Inc. Aqueous miticide containing benzyl benzoate
US6376542B1 (en) * 1997-12-19 2002-04-23 Bissell Homecare, Inc. Aqueous miticide compositions containing benzyl benzoate
MY126580A (en) * 1997-12-22 2006-10-31 Merck Sharp & Dohme Molecular dispersion composition with enchanced bioavailabity
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
DE19913606A1 (de) * 1999-03-25 2000-09-28 Basf Ag Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
DE19916383A1 (de) * 1999-03-31 2000-10-05 Schering Ag Pharmazeutische Zusammensetzung mit einem Extrusionsstoff
JP2003500439A (ja) * 1999-05-28 2003-01-07 アボット・ラボラトリーズ 脂質調節剤を含む新規調合物
DE19929361A1 (de) * 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
CA2359945C (en) * 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
DE10000792A1 (de) * 2000-01-11 2001-07-19 Bernhard C Lippold Formulierungen von Wirkstoffen in Form einer festen Dispersion
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
SK15732003A3 (sk) 2001-06-22 2005-01-03 Pfizer Products Inc. Farmaceutické kompozície zahrnujúce liečivá s nízkou rozpustnosťou a/alebo liečivá citlivé na kyselinu a neutralizované kyslé polyméry
DE60233874D1 (de) 2001-06-22 2009-11-12 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
DE60320940D1 (de) * 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
CA2479295A1 (en) * 2002-03-14 2003-09-25 Thomas C. Ho Progesterone oral drug delivery system
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
BRPI0312007B1 (pt) 2002-06-25 2015-04-14 Acrux Dds Pty Ltd Composição farmacêutica para administração transcutânea de testosterona ou fentanil e uso da dita composição
EP1592760A4 (en) 2003-01-31 2009-08-12 Smithkline Beecham Corp AS FIXED DISPERSIONS, COMPOSITIONS
CN101091695B (zh) * 2003-02-03 2011-01-19 诺瓦提斯公司 药物制剂
CA2503290C (en) 2003-03-10 2012-12-04 Altana Pharma Ag Novel process for the preparation of roflumilast
DE602004016311D1 (de) * 2003-04-29 2008-10-16 Organon Nv Verfahren zur verfestigung, bei welchem ein anti-lösungsmittel benutzt wird
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
GB0315012D0 (en) * 2003-06-27 2003-07-30 Leuven K U Res & Dev Zeotiles
US8273371B2 (en) 2003-06-27 2012-09-25 Johan Adriaan Martens Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs
BRPI0413277A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
CA2540984C (en) 2003-10-10 2011-02-08 Lifecycle Pharma A/S A solid dosage form comprising a fibrate
ATE399536T1 (de) * 2003-12-04 2008-07-15 Pfizer Prod Inc Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
CA2601250C (en) * 2005-03-16 2014-10-28 Nycomed Gmbh Taste masked dosage form containing roflumilast
WO2006112649A1 (en) * 2005-04-20 2006-10-26 Ctc Bio, Inc. Pharmaceutical composition containing sibutramine free base and manufacturing method thereof
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
DE102005023803A1 (de) * 2005-05-19 2006-11-23 Basf Ag Verfahren zur Herstellung von festen Blends aus Polyvinylpyrrolidonen und ethoxilierten Fettsäurederivaten
KR20070025070A (ko) * 2005-08-31 2007-03-08 주식회사 대웅제약 시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법
GB0612695D0 (en) * 2006-06-27 2006-08-09 Univ Gent Process for preparing a solid dosage form
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
WO2008064259A2 (en) * 2006-11-21 2008-05-29 Biokey, Inc. Solid dispersion composition comprising fluvastatin
WO2008079629A2 (en) * 2006-12-21 2008-07-03 Boehringer Ingelheim International Gmbh Formulations with improved bioavailability
EP2249808A2 (en) * 2008-01-11 2010-11-17 Cipla Limited Solid pharmaceutical dosage form
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
PT2273983T (pt) 2008-05-09 2016-10-28 Gruenenthal Gmbh Processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob utilização de uma etapa de congelamento por atomização
ES2560210T3 (es) 2009-07-22 2016-02-17 Grünenthal GmbH Forma de dosificación resistente a la manipulación para opiádes sensibles a la oxidación
CN102573805A (zh) 2009-07-22 2012-07-11 格吕伦塔尔有限公司 热熔挤出的控制释放剂型
NZ599944A (en) * 2009-10-27 2015-10-30 Lupin Ltd Solid dispersion of rifaximin
TWI516286B (zh) 2010-09-02 2016-01-11 歌林達股份有限公司 含陰離子聚合物之抗破碎劑型
RU2604676C2 (ru) 2010-09-02 2016-12-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
ES2571735T3 (es) 2010-10-20 2016-05-26 Dsm Ip Assets Bv Composiciones biodegradables que soportan grupo hidrófilo colgante y dispositivos relacionados
RU2598345C2 (ru) * 2010-10-29 2016-09-20 Эббви Инк. Твердые дисперсии, содержащие средства, вызывающие апоптоз
LT2736495T (lt) 2011-07-29 2017-11-10 Grünenthal GmbH Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu
CN103857386A (zh) 2011-07-29 2014-06-11 格吕伦塔尔有限公司 提供药物立即释放的抗破碎片剂
WO2013030789A1 (en) 2011-08-30 2013-03-07 Ranbaxy Laboratories Limited Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
CA2868142A1 (en) 2012-04-18 2013-10-24 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
KR102191562B1 (ko) * 2012-11-07 2020-12-15 에스케이바이오팜 주식회사 난용성 약물의 고체분산체 및 이의 제조방법
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
CN105682643B (zh) 2013-07-12 2019-12-13 格吕伦塔尔有限公司 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
EP3227299B1 (en) 2014-12-04 2021-05-26 Merck Sharp & Dohme Corp. Formulation inhibiting effects of low acid environment
CN107889459A (zh) 2015-04-24 2018-04-06 格吕伦塔尔有限公司 具有立即释放和对溶剂萃取的抗性的抗篡改剂型
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
CN113616599B (zh) * 2021-09-10 2022-11-18 宁夏医科大学 一种大黄素固体分散体及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983000091A1 (en) * 1981-07-08 1983-01-20 Keith, Alec, Dell Polymeric diffusion matrix containing 5-ad(3,4-dimethoxyphenethyl)methylaminobd-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
US4980378A (en) * 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
DE3839825A1 (de) * 1988-11-25 1990-06-13 Henning Berlin Gmbh Feststoffdispersionen enthaltend oxipurinol und/oder seine alkali- oder erdalkalisalze
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
KR0182801B1 (ko) 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
ES2109377T3 (es) 1991-12-18 1998-01-16 Warner Lambert Co Proceso para la preparacion de una dispersion solida.

Also Published As

Publication number Publication date
PT101132B (pt) 2000-02-29
DK0617612T3 (da) 1998-04-14
DE69222182T2 (de) 1998-02-26
IL104179A0 (en) 1993-05-13
DE69222182D1 (de) 1997-10-16
EP0617612A1 (en) 1994-10-05
PT101132A (pt) 1994-03-31
CA2124821C (en) 2003-10-07
WO1993011749A1 (en) 1993-06-24
AU671811B2 (en) 1996-09-12
JP3722293B2 (ja) 2005-11-30
GR3025501T3 (en) 1998-02-27
MX9207390A (es) 1993-06-01
IL104179A (en) 1997-11-20
NZ245483A (en) 1995-12-21
CA2124821A1 (en) 1993-06-24
US20010044409A1 (en) 2001-11-22
SG43179A1 (en) 1997-10-17
US20040110694A1 (en) 2004-06-10
EP0617612B1 (en) 1997-09-10
AU3142693A (en) 1993-07-19
US6677362B1 (en) 2004-01-13
ATE157864T1 (de) 1997-09-15
JPH07504162A (ja) 1995-05-11
ZA929789B (en) 1993-06-23

Similar Documents

Publication Publication Date Title
ES2109377T3 (es) Proceso para la preparacion de una dispersion solida.
DE59009074D1 (de) Diarylsubstituierte heterocyclische Verbindung, ihre Herstellung und Arzneimittel und Kosmetika daraus.
ATE67930T1 (de) Wirkstofftraeger und diesen enthaltende arzneimittel.
ITMI942484A0 (it) Composizioni farmaceutiche a rilascio controllato osmotico e per diffusione del farmaco e procedimento per la loro preparazione
DE69430237D1 (de) Arzneimittel zur gesteuerten Freisetzung
ATE128863T1 (de) Arzneimittelformulierungen mit verzögerter wirkstoffabgabe.
NO890075D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazoler.
DE3689983D1 (de) Arzneimittel mit langsamer Wirkstofffreisetzung.
DK0579615T3 (da) Nye estere af bi- og tricykliske aminoalkoholer, fremstilling deraf og anvendelse deraf i lægemidler
NL300206I1 (nl) R-enantiomeer van N-propargyl-1-aminoindaan, de bereiding daarvan en farmaceutische preparaten die dit bevatten.
DE59104271D1 (de) Lösungsmittelfreie, oral zu verabreichende pharmazeutische zubereitung mit verzögerter wirkstofffreisetzung und verfahren zu deren herstellung.
RU93036959A (ru) Свободно растворимый лекарственный препарат с замедленным действием биологически активных веществ, назначенный для приема внутрь, способ его производства
ATE66372T1 (de) Mikropartikel, bestehend aus einem biodegradierbaren, die freisetzung eines antimalaria-wirkstoffs kontrollierenden polymer, diese enthaltende pharmazeutische zusammensetzungen und ihr herstellungsverfahren.
ES2136591T3 (es) Derivados de cefalosporina y procedimiento para su preparacion.
DK122191A (da) Benzimidazolderivat og fysiologisk acceptable salte heraf samt fremgangsmaade til fremstilling af samme
ATE104300T1 (de) Thieno(2,3-d>azepinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
ATE234608T1 (de) Mikrokapseln mit verzögerter freisetzung von wirkstoffen
KR930017887A (ko) 약제학적 화합물
ITMI942483A0 (it) Composizioni farmaceutiche a rilascio controllato osmotico e per diffusione del farmaco e procedimento per la loro preparazione
DE69300296D1 (de) Thiochromanderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
ATE158172T1 (de) Pulverförmige pharmazeutische zusammensetzung
SE9902742D0 (sv) New pharmaceutical formultion
NO160258C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive pyridazinonimin-derivater.
DE69325531D1 (de) Oral anzuwendendes Arzneimittel bestehend aus Ibuprofen
DK22983D0 (da) Fremgangsmade til fremstilling af penicillinderivater

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 617612

Country of ref document: ES